Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance).
cohort
colonic adenocarcinoma
overall survival
physical activity
tumor recurrence
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
revised:
28
06
2023
received:
04
05
2023
accepted:
10
07
2023
medline:
6
11
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
ppublish
Résumé
One in three patients with stage III colon cancer will experience tumor recurrence. It is uncertain whether physical activity during and after postoperative chemotherapy for stage III colon cancer improves overall survival after tumor recurrence. A prospective cohort study nested within a randomized multicenter trial of patients initially diagnosed with stage III colon cancer who experienced tumor recurrence (N = 399) was conducted. Postoperative physical activity before tumor recurrence was measured. Physical activity energy expenditure was quantified via metabolic equivalent task hours per week (MET-h/week). The primary end point was overall survival after tumor recurrence. Multivariable flexible parametric survival models estimated relative and absolute effects with two-sided hypothesis tests. Compared with patients expending <3.0 MET-h/week of physical activity (comparable to <1.0 h/week of brisk walking), patients with ≥18.0 MET-h/week of physical activity (comparable to 6 h/week of brisk walking) had a 33% relative improvement in overall survival time after tumor recurrence (hazard ratio, 0.67; 95% CI, 0.42-0.96). The overall survival rate at 3 years after tumor recurrence was 61.3% (95% CI, 51.8%-69.2%) with <3.0 MET-h/week of physical activity and 72.2% (95% CI, 63.1%-79.6%) with ≥18 MET-h/week of physical activity (risk difference, 10.9 percentage points; 95% CI, 1.2-20.8 percentage points). Higher postoperative physical activity is associated with improved overall survival after tumor recurrence in patients initially diagnosed with stage III colon cancer. These data may be relevant to patients who, despite optimal postoperative medical therapy, have a high risk of tumor recurrence.
Sections du résumé
BACKGROUND
One in three patients with stage III colon cancer will experience tumor recurrence. It is uncertain whether physical activity during and after postoperative chemotherapy for stage III colon cancer improves overall survival after tumor recurrence.
METHODS
A prospective cohort study nested within a randomized multicenter trial of patients initially diagnosed with stage III colon cancer who experienced tumor recurrence (N = 399) was conducted. Postoperative physical activity before tumor recurrence was measured. Physical activity energy expenditure was quantified via metabolic equivalent task hours per week (MET-h/week). The primary end point was overall survival after tumor recurrence. Multivariable flexible parametric survival models estimated relative and absolute effects with two-sided hypothesis tests.
RESULTS
Compared with patients expending <3.0 MET-h/week of physical activity (comparable to <1.0 h/week of brisk walking), patients with ≥18.0 MET-h/week of physical activity (comparable to 6 h/week of brisk walking) had a 33% relative improvement in overall survival time after tumor recurrence (hazard ratio, 0.67; 95% CI, 0.42-0.96). The overall survival rate at 3 years after tumor recurrence was 61.3% (95% CI, 51.8%-69.2%) with <3.0 MET-h/week of physical activity and 72.2% (95% CI, 63.1%-79.6%) with ≥18 MET-h/week of physical activity (risk difference, 10.9 percentage points; 95% CI, 1.2-20.8 percentage points).
CONCLUSIONS
Higher postoperative physical activity is associated with improved overall survival after tumor recurrence in patients initially diagnosed with stage III colon cancer. These data may be relevant to patients who, despite optimal postoperative medical therapy, have a high risk of tumor recurrence.
Types de publication
Randomized Controlled Trial
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3724-3734Subventions
Organisme : NCI NIH HHS
ID : UG1 CA233290
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180821
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233163
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189954
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233234
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180882
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233180
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189867
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180868
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233339
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180863
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180820
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA271279
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA218603
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA270274
Pays : United States
Organisme : NCI NIH HHS
ID : OT2 CA278684
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180888
Pays : United States
Informations de copyright
© 2023 American Cancer Society.
Références
Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007;25(29):4569-4574. doi:10.1200/jco.2006.10.4323
Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150(3):195-203. doi:10.1002/path.1711500308
Primrose JN, Perera R, Gray A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311:263-270. doi:10.1001/jama.2013.285718
Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392-2401. doi:10.1001/jama.2017.7105
Pugh SA, Shinkins B, Fuller A, Mellor J, Mant D, Primrose JN. Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postrecurrence survival: data from the FACS randomized controlled trial. Ann Surg. 2016;263(6):1143-1147. doi:10.1097/sla.0000000000001351
Langbaum T, Smith TJ. Time to study metastatic-cancer survivorship. N Engl J Med. 2019;380(14):1300-1302. doi:10.1056/nejmp1901103
O’Connell MJ, Campbell ME, Goldberg RM, et al. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol. 2008;26(14):2336-2341. doi:10.1200/jco.2007.15.8261
Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006;24(22):3535-3541. doi:10.1200/jco.2006.06.0863
Brown JC, Ma C, Shi Q, et al. Physical activity in stage III colon cancer: CALGB/SWOG 80702 (Alliance). J Clin Oncol. 2023;41(2):243-254. doi:10.1200/jco.22.00171
Brown JC, Ma C, Shi Q, et al. Association between physical activity and the time course of cancer recurrence in stage III colon cancer. Br J Sports Med. 2023;57(15):965-971. doi:10.1136/bjsports-2022-106445
Guercio BJ, Zhang S, Ou FS, et al. Associations of physical activity with survival and progression in metastatic colorectal cancer: results from Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Clin Oncol. 2019;37(29):2620-2631. doi:10.1200/jco.19.01019
Jeon J, Sato K, Niedzwiecki D, et al. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: findings from CALGB 89803/Alliance. Clin Colorectal Cancer. 2013;12(4):233-238. doi:10.1016/j.clcc.2013.06.005
Meyerhardt JA, Shi Q, Fuchs CS, et al. Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB/SWOG 80702 (Alliance) randomized clinical trial. JAMA. 2021;325(13):1277-1286. doi:10.1001/jama.2021.2454
Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378(13):1177-1188. doi:10.1056/nejmoa1713709
Andre T, Iveson T, Labianca R, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: trial design and current status. Curr Colorectal Cancer Rep. 2013;9(3):261-269. doi:10.1007/s11888-013-0181-6
Wolf AM, Hunter DJ, Colditz GA, et al. Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol. 1994;23(5):991-999. doi:10.1093/ije/23.5.991
Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32(suppl):S498-S504. doi:10.1097/00005768-200009001-00009
Glass S, Dwyer GB, American College of Sports Medicine, eds. ACSM’s Metabolic Calculations Handbook. Lippincott Williams & Wilkins; 2007.
Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985;122(1):51-65. doi:10.1093/oxfordjournals.aje.a114086
Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007;298(7):754-764. doi:10.1001/jama.298.7.754
Hu FB, Stampfer MJ, Rimm E, et al. Dietary fat and coronary heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary measurements. Am J Epidemiol. 1999;149(6):531-540. doi:10.1093/oxfordjournals.aje.a009849
Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175-2197. doi:10.1002/sim.1203
Rutherford MJ, Crowther MJ, Lambert PC. The use of restricted cubic splines to approximate complex hazard functions in the analysis of time-to-event data: a simulation study. J Stat Comput Simul. 2013;85(4):777-793. doi:10.1080/00949655.2013.845890
Jackson CH. flexsurv: a platform for parametric survival modeling in R. J Stat Softw. 2016;70:i08. doi:10.18637/jss.v070.i08
Lloyd CJ. Bootstrap and second-order tests of risk difference. Biometrics. 2010;66(3):975-982. doi:10.1111/j.1541-0420.2009.01354.x
VanderWeele TJ. Principles of confounder selection. Eur J Epidemiol. 2019;34(3):211-219. doi:10.1007/s10654-019-00494-6
Harrell F. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. Springer; 2015.
VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268-274. doi:10.7326/m16-2607
Brown JC, Ma C, Shi Q, et al. The Time-Course of Cancer Recurrence with Physical Activity in Stage III Colon Cancer. CALGB/SWOG 80702 (Alliance); 2022.
McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. Physical activity in cancer prevention and survival: a systematic review. Med Sci Sports Exerc. 2019;51(6):1252-1261. doi:10.1249/mss.0000000000001937
Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol. 2005;23(24):5814-5830. doi:10.1200/jco.2005.01.230
Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis. Oncologist. 2021;26(9):e1609-e1618. doi:10.1002/onco.13822
Galizia G, Lieto E, Orditura M, et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg. 2008;143(4):352-358. doi:10.1001/archsurg.143.4.352
Brown JC, Damjanov N, Courneya KS, et al. A randomized dose-response trial of aerobic exercise and health-related quality of life in colon cancer survivors. Psychooncology. 2018;27(4):1221-1228. doi:10.1002/pon.4655
Dunne DF, Jack S, Jones RP, et al. Randomized clinical trial of prehabilitation before planned liver resection. Br J Surg. 2016;103(5):504-512. doi:10.1002/bjs.10096
Older PO, Levett DZH. Cardiopulmonary exercise testing and surgery. Ann Am Thorac Soc. 2017;14(suppl 1):S74-S83. doi:10.1513/annalsats.201610-780fr
Ahn KY, Hur H, Kim DH, et al. The effects of inpatient exercise therapy on the length of hospital stay in stages I-III colon cancer patients: randomized controlled trial. Int J Colorectal Dis. 2013;28(5):643-651. doi:10.1007/s00384-013-1665-1
Brown JC, Rhim AD, Manning SL, et al. Effects of exercise on circulating tumor cells among patients with resected stage I-III colon cancer. PLoS One. 2018;13(10):e0204875. doi:10.1371/journal.pone.0204875
Toffoli EC, Sweegers MG, Bontkes HJ, et al. Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: a randomized pilot study. Phys Rep. 2021;9(11):e14919. doi:10.14814/phy2.14919
Garner H, de Visser KE. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol. 2020;20(8):483-497. doi:10.1038/s41577-019-0271-z
Brown JC, Zhang S, Ligibel JA, et al. Effect of exercise or metformin on biomarkers of inflammation in breast and colorectal cancer: a randomized trial. Cancer Prev Res. 2020;13(12):1055-1062. doi:10.1158/1940-6207.capr-20-0188
Brown JC, Rickels MR, Troxel AB, et al. Dose-response effects of exercise on insulin among colon cancer survivors. Endocr Relat Cancer. 2018;25(1):11-19. doi:10.1530/erc-17-0377
Bergers G, Fendt SM. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21(3):162-180. doi:10.1038/s41568-020-00320-2
Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720-2726. doi:10.1001/jama.291.22.2720